Sign in: Staff/Students
The new treatments are intended to enable the patient to tolerate disease, and buy the immune system valuable time to get rid of the infection naturally
New types of drugs intended for use in place of antibiotics have been given a cautious welcome by scientists at the Universities of Liverpool and Edinburgh.
Researchers have been probing the long-term effectiveness of drugs being developed by the pharmaceutical industry. These work by limiting the symptoms caused by a bug or virus in the body, rather than killing it outright.
These treatments are designed to avoid the problem of infections becoming resistant to treatment, which has become widespread with antibiotics.
This approach is intended to enable the patient to tolerate disease, and buy the immune system valuable time to get rid of the infection naturally.
They found that for infections where the symptoms are not linked to the spread of disease, these drugs may prevent disease from evolving too quickly. They will be useful over longer periods of time.
However, parasitologist, Dr Andy Fenton, from Liverpool’s Institute of Integrative Biology cautions that people given damage limitation treatments may appear healthy, but carry high levels of infection and so may be more likely to pass on disease. In addition, people with lesser symptoms could remain undiagnosed and add to the spread of disease.
“Antibiotic resistance is a serious issue and these alternatives offer hope in solving the problem,” he said.
“However we should be cautious as it’s possible that in some cases these drugs may cause disease to spread.”
The study, ‘Limiting Damage during Infection: Lessons from Infection Tolerance for Novel Therapeutics’, was published in PLoS Biology. Read it here
You must be logged in to post a comment.
All recent news
New website to help families and professionals navigate the complexities of missing persons
£1.25M to design revolutionary upper body mobility suit for progressive neuromuscular diseases
Study sheds light on monkeypox in the UK
Race equality: our commitment and progress
Professor Tom Solomon appointed Director of The Pandemic Institute
Congratulations to Professor Tom Solomon on his appointment as the new Director of The Pandemic Institute! Read more about this story and the exciting new funding call focusing on the unprecedented spread of monkey pox outside of African countries here: https://tinyurl.com/PandemicInstituteDirector
Dr @farnaznickpour & @inclusionaries_ lab are part of an innovative project with @DuchenneUK & @SMA_UK awarded £1.25M from @PostcodeLottery to design a revolutionary upper body mobility suit for progressive neuromuscular diseases.
Find out more: http://bit.ly/3LKjtQb
As part of our celebrations to mark the opening of the Digital Innovation Facility (@DIF_Liverpool), Dr Andy Levers talked to @LivUniAlumni Sir Robin Saxby about the new facility, digital technologies & his love for Liverpool.
Find out more: http://bit.ly/3GsIVJ70